Kudo T
Ann Nucl Cardiol. 2024; 10(1):4-5.
PMID: 39635324
PMC: 11612403.
DOI: 10.17996/anc.24-00004.
Delbarre M, Chadha G, Annabi M, Nouri R, Zaroui A, Blanc-Durand P
J Intern Med. 2024; 297(2):186-200.
PMID: 39610264
PMC: 11771575.
DOI: 10.1111/joim.20042.
Egi R, Matsusaka Y, Watanabe K, Seto A, Matsunari I, Arai T
Nucl Med Commun. 2024; 46(1):38-46.
PMID: 39483085
PMC: 11634134.
DOI: 10.1097/MNM.0000000000001922.
Fraix A, Itti E, Zaroui A, Kharoubi M, Poullot E, Lerman L
Orphanet J Rare Dis. 2024; 19(1):381.
PMID: 39407234
PMC: 11481466.
DOI: 10.1186/s13023-024-03401-9.
Miller E, Campisi R, Shah N, McMahon S, Cuddy S, Gallegos-Kattan C
J Nucl Cardiol. 2022; 29(5):2748-2760.
PMID: 35838892
PMC: 9285188.
DOI: 10.1007/s12350-022-03059-5.
Characteristics and natural history of early-stage cardiac transthyretin amyloidosis.
Law S, Bezard M, Petrie A, Chacko L, Cohen O, Ravichandran S
Eur Heart J. 2022; 43(27):2622-2632.
PMID: 35608040
PMC: 9279112.
DOI: 10.1093/eurheartj/ehac259.
Quantitative Tc-DPD-SPECT/CT assessment of cardiac amyloidosis.
Kessler L, Fragoso Costa P, Kersting D, Jentzen W, Weber M, Ludike P
J Nucl Cardiol. 2022; 30(1):101-111.
PMID: 35562639
PMC: 9984322.
DOI: 10.1007/s12350-022-02960-3.
Suspicion, screening, and diagnosis of wild-type transthyretin amyloid cardiomyopathy: a systematic literature review.
Bay K, Gustafsson F, Maiborg M, Bagger-Bahnsen A, Strand A, Pilgaard T
ESC Heart Fail. 2022; 9(3):1524-1541.
PMID: 35343098
PMC: 9065854.
DOI: 10.1002/ehf2.13884.
Variability in bone-seeking tracers and imaging protocols for the diagnosis of cardiac amyloidosis: The more the merrier?.
Weiler-Sagie M, Ben-Haim S
J Nucl Cardiol. 2020; 29(1):319-322.
PMID: 32895861
DOI: 10.1007/s12350-020-02330-x.
Cardiac amyloidosis detection by early bisphosphonate (99mTc-HMDP) scintigraphy.
Santarelli M, Genovesi D, Positano V, Di Sarlo R, Scipioni M, Giorgetti A
J Nucl Cardiol. 2020; 29(1):307-318.
PMID: 32596791
DOI: 10.1007/s12350-020-02239-5.
Quantification of myocardial Tc-labeled bisphosphonate uptake with cadmium zinc telluride camera in patients with transthyretin-related cardiac amyloidosis.
Manrique A, Dudoignon D, Brun S, Nganoa C, Cassol E, Legallois D
EJNMMI Res. 2019; 9(1):117.
PMID: 31873816
PMC: 6928186.
DOI: 10.1186/s13550-019-0584-8.
ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging.
Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk R, Ferrari V
J Nucl Cardiol. 2019; 26(6):2065-2123.
PMID: 31468376
DOI: 10.1007/s12350-019-01760-6.
Role of cardiovascular imaging for the diagnosis and prognosis of cardiac amyloidosis.
Agha A, Parwani P, Guha A, Durand J, Iliescu C, Hassan S
Open Heart. 2018; 5(2):e000881.
PMID: 30305910
PMC: 6173267.
DOI: 10.1136/openhrt-2018-000881.
Analogies and disparities among scintigraphic bone tracers in the diagnosis of cardiac and non-cardiac ATTR amyloidosis.
Rapezzi C, Gagliardi C, Milandri A
J Nucl Cardiol. 2018; 26(5):1638-1641.
PMID: 29473120
DOI: 10.1007/s12350-018-1235-6.
Apical sparing pattern of left ventricular myocardial Tc-HMDP uptake in patients with transthyretin cardiac amyloidosis.
Van Der Gucht A, Cottereau A, Abulizi M, Guellich A, Blanc-Durand P, Israel J
J Nucl Cardiol. 2017; 25(6):2072-2079.
PMID: 28447284
DOI: 10.1007/s12350-017-0894-z.
Early-phase myocardial uptake intensity of Tc-HMDP vs Tc-DPD in patients with hereditary transthyretin-related cardiac amyloidosis.
Abulizi M, Cottereau A, Guellich A, Vandeventer S, Galat A, Van Der Gucht A
J Nucl Cardiol. 2016; 25(1):217-222.
PMID: 27804073
DOI: 10.1007/s12350-016-0707-9.
